Evidence map›Paper›PMID 36637794›Full record

ArticleJournal of the American Geriatrics Society2023

"Worth it if you could afford it": Patient perspectives on integrating real-time benefit tools into drug cost conversations.

T Joseph Mattingly, Jordan Everson, Robert J Besaw, Christine C Whitmore, Sarah C Henderson, Stacie B Dusetzina

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of the American Geriatrics Society, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
2.3field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

T Joseph MattinglyDepartment of Pharmaceutical Health Services Research, University of Maryland School of Pharmacy, Baltimore, Maryland, USA.ORCID 0000-0001-7786-5780
Jordan EversonDepartment of Health and Human Services, Data Analysis Branch, Office of the National Coordinator for Health Information Technology, Washington, District of Columbia, USA.
Robert J BesawDepartment of Health Policy, Vanderbilt University School of Medicine, Nashville, Tennessee, USA.
Christine C WhitmoreDepartment of Health Policy, Vanderbilt University School of Medicine, Nashville, Tennessee, USA.
Sarah C HendersonDepartment of Health Policy, Vanderbilt University School of Medicine, Nashville, Tennessee, USA.
Stacie B DusetzinaDepartment of Health Policy, Vanderbilt University School of Medicine, Nashville, Tennessee, USA.
Vanderbilt University · USOffice of the National Coordinator for Health Information Technology · USUniversity of Maryland, Baltimore · US

Funding

Vanderbilt Institute for Clinical and Translational Research (VICTR) -Identifying correlates of functional immunity in SARS-CoV-2 convalescent plasmaUL1TR002243 · NCATS · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Paul A. Harris, Wesley H Self · 2017 to 2026
$130.7M
NCATS NIH HHS UL1 TR002243
6 · The paper itself

Abstract

backgroundMedication costs can lead to financial burdens for patients, creating barriers to effective medication use. Health care provider use of real-time benefit tools (RTBTs) may facilitate cost conversations with patients. We sought to explicate patient views on how RTBTs could be used to improve cost considerations in prescribing decisions.

methodsWe conducted focus groups to characterize patient perspectives on holding cost conversations with their physicians and to identify factors that would influence the value of RTBTs. We focused on adults aged 50+ who reported trouble paying for their prescriptions. Three groups included patients with conditions requiring high-cost treatments and one group included lower-income patients independent of their medical conditions. Focus groups were recorded, transcribed, coded, and categorized to salient themes employing inductive and deductive approaches using the Health Equity Implementation Framework.

resultsFocus groups were conducted from 09/2020-12/2020 including 18 participants representing cancer (n = 6), diabetes (n = 6), rheumatoid arthritis (n = 3), and lower income (n = 3). Participants were between 50-74, eight self-identified as Black, 10 as White, and eight reported earning <$50,000/year. We identified five themes regarding cost conversations (medication cost importance, past experiences with cost/cost conversations, perception of physician's role and knowledge, knowledge of existing resources, and influence on decision-making) and four RTBT-use-specific themes (advantages/disadvantages, perceived relevance, data quality concerns, and implementation considerations).

conclusionApproaches that envision RTBTs as one-size-fits-all technological interventions may underestimate the complexity of incorporating price information into prescribing decisions. Nevertheless, patients highlighted the potential value of accurate, real-time information on medication costs to inform decision-making.

Indexed as

Diabetes MellitusNeoplasmsDrug CostsFocus GroupsHealth Care CostsHumanscost of illnesspatient engagementpatient-provider relationshippharmacy benefitsprescriber tools

Identifiers

PMID36637794
OpenAlexW4315927704

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.